Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii

  • J Antibiot (Tokyo). 1999 Mar;52(3):245-55. doi: 10.7164/antibiotics.52.245.
J Qian-Cutrone  1 ,  T Ueki ,  S Huang ,  K A Mookhtiar ,  R Ezekiel ,  S S Kalinowski ,  K S Brown ,  J Golik ,  S Lowe ,  D M Pirnik ,  R Hugill ,  J A Veitch ,  S E Klohr ,  J L Whitney ,  S P Manly
Affiliations
  • 1. Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492, USA.
PMID: 10348039 DOI: 10.7164/antibiotics.52.245
Abstract

During the screening of the natural products for their ability to increase the activity of Glucokinase by relieving inhibition by long chain fatty acyl CoA esters (FAC), two novel compounds, glucolipsin A (1) and B (2) were isolated from the butanol extracts of Streptomyces purpurogeniscleroticus WC71634 and Nocardia vaccinii WC65712, respectively. The structures of these two compounds were established by spectroscopic methods and chemical degradation. Glucolipsin A (1) and B (2) relieved the inhibition of Glucokinase by FAC with RC50 values of 5.4 and 4.6 microM.

Products